What is the future holding for the use of antibiotics and the fight against resistance?

Miguel Ángel Higuera
14-Sep-2017 (8 years 8 months 23 days ago)

The use of antibiotics in both human and veterinary medicine is in the spotlight due to the threat posed by the emergence and development of resistance. The European Union has faced the challenge with its own strategy, which results are beginning to be seen. What will happen to antibiotics in the European Union? Let us try to review the current situation and what is coming.

Regulations under development

EU legislation on veterinary medicinal products and medicated feed is currently being reviewed.

Experts have been working on the proposal for the regulation of veterinary drugs since 2014. At the same time, the regulatory proposal for the amendment of the regulation on medicated feed —which will affect its manufacture, launching and use—, is being revised.

Antimicrobial resistance (AMR) is, globally, a serious problem. Irresponsible use of antibiotics in human and veterinary medicine can contribute to the development of AMR. These new normative proposals derive from the Commission's Strategy to fight this threat, being the measures to control this problem very much on the agenda. This debate confirms the need for a clear scientific approach to be able to establish realistic and effective measures.

With regard to the regulation of veterinary medicines, the debate focuses on:

In medicated animal feed, the main points of the debate include:

Control of antibiotic consumption

One of the main issues is the excessive use of antibiotics. To find out its real volume, a voluntary participation report is drawn up annually to collect the volume of antimicrobial sales in the EU, the ESVAC (European Surveillance of Veterinary Antimicrobial Consumption) report, which contains data from 2010 (19 countries), 2011 (25 countries), 2012 (26 countries), 2013 (26 countries) and 2014 (29 countries).

The evolution of total sales in tonnes of active ingredient and mg/PCU of the countries participating in the ESVAC report can be seen in the following tables.

<p>Graph 1. Evolution of total antimicrobial sales in the countries analysed in the ESVAC report.</p>

<p>Graph 2. Evolution of antimicrobial sales in mg / PCU in the countries analyzed in the ESVAC report.</p>

Regarding the consumption of antimicrobials per PCU unit, the average for the countries included in the ESVAC 2014 report was 107.84 mg/PCU.

The mg/PCU unit is a system developed to allow for a valid comparison of the use of antimicrobials between countries by comparing the mg of active ingredient sold for the domestic market of that country, with the units of animal product produced. In the case of swine, the Population Correction Unit (PCU) is obtained from the sum of the average census of breeding stock and animals produced for slaughter, estimating an average weight of 240 and 65 kg respectively. These data must be corrected by subtracting or adding, the import and/or export of piglets and/or pigs for slaughter.

Current normative review

EU legislation on veterinary medicinal products, including antibiotics, aims at ensuring a high level of health protection and promoting the functioning of the internal market, while helping to encourage innovation. The most important ones are:

Conclusion

The fight against antimicrobial resistance has put in focus the consumption of antibiotics in particular, and of antimicrobials in general. In line with the European Commission's strategy to fight resistance, the rules on veterinary medicines and medicated feeding stuffs will be modified. The aim is to make a responsible use of antibiotics with a double aim: to reduce, if possible, antimicrobial resistance and, on the other hand, to have effective antibiotics for a long time. Antibiotics are and will be necessary, therefore an effort must be made to preserve them.